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Key Findings:
It should be noted that the ordering of the 
key findings below is according to the order of 
appearance in the bulletin and is not intended 
to reflect the order of importance of the findings.
Sedatives or Tranquillisers
Sedatives or Tranquillisers are commonly used 
terms for the same group of medicines which 
depress, slow down or calm the brain and central 
nervous system.
u Prevalence rates for sedatives or 
tranquillisers are 13.1% for lifetime use, 
6.1% for last year, and 3.3% for last month 
use.
u Prevalence rates are significantly higher 
among females compared to males for 
lifetime (15.3% vs 10.8%), last year 
(7.7% vs 4.4%) and last month (4.1% vs 
2.4%). Prevalence rates are also statistically 
significantly higher for older (i.e. 35-64 
y/o) than younger (i.e. 15-34 y/o) adults 
for lifetime (16.3% vs 8.9%), last year 
(7.7% vs 4.1%) and for last month (4.6% 
vs 1.6%). Those over 65 have the highest 
prevalence rates for lifetime (21.4%), last 
year (12.7%) and last month (10.9%).
u The median age of first use of sedatives or 
tranquillisers is 30 years. This is unchanged 
since the previous survey.
u The majority of people who used sedatives 
or tranquillisers in the last month report 
using sedatives or tranquillisers on 20 days 
or more in the month prior to the survey 
(58.9%), an increase on the 2010/11 
proportion (53.3%). This rate is higher in 
males than females (68.3% vs. 53.6%) 
and for older adults (64.1%) than younger 
adults (39.3%).
u Lifetime (21.8%), last year (12.3%) and 
last month rates (9.4%) of sedative or 
tranquilliser use are highest among those 
classified as Group E (All those dependent 
on the state long term).
u For prevalence of sedatives or tranquillisers 
by housing tenure, last year and last month 
rates are highest for those renting from local 
authority/housing authority (12.2% and 
8.6% respectively).
u The results show that levels of lifetime, last 
year and last month tranquilliser or sedative 
use decreases as years of education 
increases. All prevalence rates are lowest 
among those who ceased education at 
20 years or over. Rates are highest among 
those who ceased education at 15 years 
or under.
u All prevalence rates are lowest for those 
whose highest level of education is upper 
secondary. The highest prevalence rates are 
for those who have no formal education or 
only primary level education.
u According to marital status, lifetime and last 
year rates are highest for those who are 
divorced and last month rates are highest 
for those who are widowed.
Anti-Depressants
These are medicines to treat depression
u Prevalence rates for anti-depressants 
are 11.6% for lifetime use, 5.9% for last 
year, and 4.8% for last month. Last year 
use (5.9% up from 4.8%) represents a 
statistically significant increase on 2010/11 
result.
u Prevalence rates are significantly higher 
among females compared to males for 
lifetime (14.5% vs 8.6%), last year (7% 
vs 4.8%) and last month (5.7% vs 3.9%). 
Last year use (14.5%, up from 12.4%) by 
females showed a statistically significant 
increase on 2010/11 result. Prevalence 
rates were also statistically higher for older 
than younger adults for lifetime (14.2% 
vs 8.3%), last year (7.4% vs 4%) and 
for last month (6.2% vs 3%).
u The median age of first use of anti-
depressants is 30 years. This is unchanged 
since the previous survey.
u The majority of people who used anti-
depressants in the last month report using 
on 20 days or more in the month prior to 
the survey (92.7%), a slight increase on 
the 2010/11 proportion (92.4%). This 
rate is slightly higher in males than females 
(93.6% vs. 92%) and for older adults 
(93.6%) than younger adults (90.2%).
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u Lifetime (19.4%), last year (10.4%) and 
last month rates (9%) of anti-depressant 
use are highest among those classified as 
Group E (All those dependent on the state 
long term).
u For housing tenure, lifetime (24.5%) last 
year (12.9%) and last month (9.9%) 
prevalence rates for anti-depressant use 
are highest for those renting from local 
authority/housing authority.
u The results show that levels of lifetime, last 
year and last month anti-depressant use 
decrease as years of education increases. 
All prevalence rates are lowest among those 
who ceased education at 20 years or over. 
All prevalence rates are highest for those 
who ceased education at 15 years or under.
u Lifetime and last year prevalence rates are 
lowest for those whose highest level of 
education is upper secondary. Last month 
prevalence is lowest for those whose 
highest level of education is third level. 
Lifetime and last month prevalence rates 
are highest for those who have no formal 
education or only primary level education. 
Last year prevalence rates are highest for 
those who attained lower secondary level 
education or no formal education/primary 
education.
u According to marital status, all prevalence 
rates are highest for those who are 
separated.
Other Opiates
The term ‘other opiates’ relates to opiates other 
than heroin and methadone and includes a 
number of drugs, most commonly codeine.
For the complete list of drugs included in the 
term ‘other opiates’ please see the showcard in 
the appendix that was presented to respondents 
during the survey.
u Prevalence rates for other opiates are 
63.8% for lifetime use, 45.8% for last year, 
and 21% for last month use.
u Prevalence rates are significantly higher 
among females compared to males for 
lifetime (68.2% vs 59.4%), last year 
(51.1% vs 40.5%) and last month 
(25.6% vs 16.3%). Over 65s had the 
lowest prevalence rates for lifetime (49%), 
last year (29.7%) and last month (13.5%).
u The median age of first use of other opiates 
is 18 years.
u The majority (58.8%) of people who used 
other opiates in the last month report using 
other opiates on 1-3 days in the month 
prior to the survey. This is slightly higher 
in females than males (59.7% vs. 57.5%) 
and for younger adults (61.2%) than older 
adults (56.8%).
u Lifetime (71.3%) and last year (53%) use 
of other opiates are highest among those 
classified as Group B (Middle management, 
senior civil servants, managers and owners 
of own business).
u For prevalence by housing tenure, lifetime 
(63.7%), last year (52.4%) and last month 
(22.1%) prevalence rates for other opiates 
are highest for those who live with parents/
other family.
u The results show that levels of lifetime, 
last year and last month other opiate use 
increase as years of education increases. 
All prevalence rates are highest among 
those who ceased education at 20 years 
or over. Rates are lowest among those 
who ceased education at 15 years or under.
u All prevalence rates are lowest for those 
with no formal education or primary 
education only. Prevalence rates are 
highest for those who attained a third 
level education.
u According to marital status, lifetime and last 
month rates are highest for those who are 
separated. Last year rates are highest for 
those who are single/never married.
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Introduction
This bulletin presents findings regarding the use 
of prescription drugs in Ireland from the fourth 
drug prevalence survey of households in Ireland 
and Northern Ireland. Within Ireland the survey 
sampled a representative number of people 
aged 15+ from August 2014 to August 2015. 
The bulletin presents results regarding use of 
prescription drugs on lifetime (ever used), last 
year (recent use) and last month (current use) 
prevalence rates for Ireland. Finally the bulletin 
examines a range of important issues including 
age of first use, frequency of use, methods of 
using prescription drugs, how prescription drugs 
are obtained and the profile of those who take 
them. The survey was carried out according 
to standards set by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA).
The Drug Prevalence Survey 2014/15 for the 
Republic of Ireland introduced a number of 
key changes to the questionnaire and sample 
population targeted, most notably;
u The sample population was extended from 
15-64 years to include all those aged 15+ 
years.
u A new section focusing on gambling 
prevalence was included.
These changes, therefore, require some 
modification of the bulletin layout to ensure that 
the valuable insights garnered from the trend data 
of 15-64 year olds is continued, but also to ensure 
that the 2014/15 data of all those aged 15+ is 
adequately addressed.
The survey was commissioned by the National 
Advisory Committee on Drugs and Alcohol 
(NACDA) in Ireland and the Public Health 
Information & Research Branch (PHIRB) within 
the Department of Health, in Northern Ireland. 
The main focus of the survey was to obtain 
prevalence rates for key illegal drugs, such as 
cannabis, ecstasy, cocaine and heroin on a 
lifetime (ever used), last year (recent use), and 
last month (current use) basis. Similar prevalence 
questions were also asked of alcohol, tobacco, 
and other drugs (e.g. tranquillisers); attitudinal and 
demographic information was also sought from 
respondents.
Methodology
The questionnaire and methodology for this 
general population survey were based on best 
practice guidelines drawn up by the EMCDDA. 
The questionnaires were administered through 
face-to-face interviews with respondents aged 
15+ years in Ireland who are normally resident 
in households. Thus persons outside these age 
ranges, or who do not normally live in private 
households, have not been included in the 
survey (for example prisons, nursing homes etc.).
Fieldwork for the survey was carried out between 
August 2014 and August 2015 and the final 
achieved sample comprised of 7,005 respondents 
in the Republic of Ireland. The response rate for 
the survey was 61%.
Area-based sampling was applied. A three-stage 
process was used to construct the sample for 
this survey. The first stage involved stratifying 
by former Health Board regions in Ireland 
and sampling within each Health Board was 
primarily in proportion to the population. The 
achieved sample was weighted by gender, age 
and former Health Board region to maximise 
its representativeness of the general population. 
Details of the methodology can be found in the 
technical report.
Interviews were conducted using computer-
assisted personal interviewing (CAPI). These 
techniques allow interviews to be conducted 
more efficiently and more accurately than other 
techniques, such as pen-and-paper completion.
Reliability of the Estimates
The tests of statistical significance are used to 
establish the degree of confidence with which 
we can infer that the observed changes in drug 
prevalence between 2014/15 and 2010/11 
are not due to sampling error. For the change 
in prevalence over time, a significance level of 
5% has been specified which means that the 
likelihood that sampling error accounts for the 
observed change is less than 5%. More stringent 
criteria are used for the tests of association; for 
instance between prevalence and socio-economic 
group, significance levels of 1% and 0.1% are 
used.
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In statistical testing, a result is deemed statistically 
significant if it is unlikely to have occurred by 
chance, and hence provides enough evidence 
to reject the hypothesis of ‘no effect’. As used in 
statistics, significant does not mean important or 
meaningful. A small, but important, real-world 
difference may fail to reach significance in a 
statistical test. Conversely, a statistically significant 
finding may have no practical consequence. This is 
especially important to remember when working 
with large sample sizes because any difference 
can be statistically significant if the samples are 
extremely large. Whether the change is of practical 
importance is reflected in an evaluation of effect 
size, which is a substantive issue.
Limitations of the General 
Population Survey Methodology
A general population drug prevalence survey 
has some limitations. Some groups with high 
drug use prevalence are not covered by the 
general population survey method (for example 
the homeless, those in prison etc.). Additionally, 
drug prevalence questions are considered to be 
sensitive and therefore people may refuse to 
participate or they may under-report their drug 
use. Moreover, for some groups the numbers can 
be too small for reliable prevalence estimations 
and for these specific groups, general population 
prevalence estimates can be supplemented by 
other methods (e.g. capture-recapture for problem 
drug use and surveys targeting special populations 
(e.g. prisoners, students, early school leavers)).
What is prevalence?
The term prevalence refers to the proportion of a 
population who have used a drug over a particular 
time period. In general population surveys, 
prevalence is measured by asking respondents in a 
representative sample drawn from the population 
to recall their use of drugs. The three most widely 
used recall periods are: lifetime (ever used a drug), 
last year (used a drug in the last twelve months), 
and last month (used a drug in the last 30 days). 
Provided that a sample is representative of the 
total population, prevalence information obtained 
from a sample can be used to infer prevalence in 
the population.
Lifetime prevalence refers to the proportion of the 
sample that reported ever having used the named 
drug at the time they were surveyed. A person 
who records lifetime prevalence may or may not 
be currently using the drug. Lifetime prevalence 
should not be interpreted as meaning that people 
have necessarily used a drug over a long period of 
time or that they will use the drug in future.
Last year prevalence refers to the proportion of 
the sample that reported using a named drug in 
the year prior to the survey. Last year prevalence is 
often referred to as recent use.
Last month prevalence refers to the proportion of 
the sample that reported using a named drug in 
the 30-day period prior to the survey. Last month 
prevalence is often referred to as current use. A 
proportion of those reporting current use may 
only use occasionally (or for the first-time) and 
happen to have used in the period leading up to 
the survey. It should therefore be appreciated that 
current use is not synonymous with regular use.
Understanding the Results of 
this Bulletin
This bulletin contains prevalence rates and 
other relevant information regarding the use of 
prescription drugs in Ireland for 2014/15. Results 
are given for all respondents (all adults aged 15+ 
years) and for gender and age (15-34, 35-64 and 
65+ years) categories.
Those over 65 were included in the Republic 
of Ireland survey for the first time in 2014/15, 
therefore the current results report prevalence 
levels of all those aged 15+ years, while the 
comparative results are provided for those aged 
15-64 years.
Comparisons between 2014/15 and the 2010/11 
survey results are presented for prevalence, 
frequency of use, age of first use.
Statistical significance tests for changes over time 
have been undertaken and changes that reach 
the threshold for statistical significance have been 
reported (for further details see below). The 
figures for 2006/7 and 2002/3 in Ireland reported 
in this bulletin may differ slightly from figures 
report in earlier publications. These differences 
are due to the application of improved estimation 
procedures for comparing data over time. The 
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2010/11 data presented in this bulletin has not 
been adjusted since its publication.
All prevalence rates presented in the 
accompanying tables are rounded to one decimal 
place. As in all sample surveys, the greater the 
sample size the more statistically reliable are the 
results. Some of the differences in prevalence rates 
in the tables will be attributable to natural sample 
variations. Percentages may not always sum to 
100 due to either the effect of rounding or that 
respondents could give more than one answer.
Glossary
For the complete list of drugs included in the 
terms sedative or tranquillisers and ‘other opiates’ 
please see the showcards that were presented to 
respondents during the survey, and are located in 
the appendix.
Sedatives or Tranquillisers
Sedatives or tranquillisers are commonly used 
terms for the same group of medicines which 
depress, slow down or calm the brain and central 
nervous system. They are mainly Benzodiazepines 
(“Benzos”) but other drugs with the same effects 
e.g. Zolpidem and Zopiclone are included in this 
group. Medically they are often referred to as 
hypnotics, which induce sleep, and anxiolytics 
or anti-anxiety agents.
The same drug can be used as a hypnotic or 
as an anti-anxiety agent depending on the 
dosage used and on the time of day that they 
are used. Hypnotics are used to treat insomnia 
(lack of adequate restful sleep) that is causing 
distress. Anxiolytics are often referred to as ‘minor 
tranquillisers’. Benzodiazepines anxiolytics are the 
most common type used to obtain relief of severe 
and disabling anxiety.
Anti-depressants
These are medicines used to treat conditions such 
as low or sad mood, loss of interest or pleasure 
in daily activities, fatigue and energy loss usually 
known as depression. Different drug classes are 
available on prescription to treat depression. These 
drugs are prescribed under medical supervision.
Other Opiates
The term ‘other opiates’ relates to opiates other 
than heroin and methadone and includes a 
number of drugs, but most commonly codeine. 
The category includes medicines that are available 
over-the-counter or on prescription. Although the 
medicines listed in the category ‘other opiates’ are 
legal, they can still be highly addictive and can be 
misused.
The medicines included are: Codeine, DF 118 30 
tablets, Feminax, Kapake, Migraleve, Nurofen Plus, 
Panadeine tablets, Paracodin, Paramol, Solpadeine, 
Solpadol, Syndol, Tylex, Unifu Plus with Vitamin C, 
Veganin Plus, Tramadol, Opiates (excluding heroin 
& methadone), Temgesic®, Kapake®, Morphine, 
Opium, DF118 ® (DF’s), Diffs, Dikes, Peach, 
Fentanyl (Durogesic ® & Sublimaze ® & Actiq ®), 
Oxycodone (Oxycontin ® & Oxynorm ®), MST ® 
(MST’s), Buprenorphine (Subutex ®), Diconal ®, 
Pethidine, Napps.
SOC2000 Classification
In Ireland, socio-economic grouping is based on 
a classification of occupation and coded to the 
Standard Occupation Classification 2000.
A Professionals, senior management and top 
civil servants
B Middle management, senior civil servants, 
managers and owners of business
C1 Junior management and owners of small 
businesses
C2 Skilled manual workers and manual workers 
responsible for other workers
D Semi-skilled and unskilled manual workers, 
trainees and apprentices
E All those dependent on the State long-term
F1 Farmer 50+ acres
F2 Farmer < 50 acres
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Results
Prevalence Rates and Comparisons between 2010/11 and 2014/15
Table 1.1.1: Sedatives or Tranquillisers Prevalence Rates (Adults 15-64) by Gender (%)
All adults (15-64) Male (15-64) Female (15-64)
06/07 10/11 14/15 06/07 10/11 14/15 06/07 10/11 14/15
Total Weighted N (valid responses) 4967 5127 5937 2513 2553 2957 2454 2574 2980
Lifetime prevalence (Ever used) 10.6 13.9 13.1 8.1 12.4 10.8 13.2 15.5 15.3a
Last year prevalence 4.7 6.5 6.1 3.7 5.7 4.4 5.7 7.3 7.7a
Last month prevalence 3.0 2.8 3.3 2.4 2.3 2.4 3.6 3.3 4.1a
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Statistically significant changes (p<0.05) between 10/11 and 14/15
a Statistically significant differences (p<0.001) between males and females were found for 2014/15
Table 1.1.2: Sedatives or Tranquillisers Prevalence Rates (Adults 15+) by Age (%)
Young Adults 15-34 Older Adults 35-64 65+
06/07 10/11 14/15 06/07 10/11 14/15 14/15
Total Weighted N (valid responses) 2315 2254 2592 2652 2873 3345 1039
Lifetime prevalence (Ever used) 5.9 10.1 8.9 14.7 16.9 16.3b 21.4
Last year prevalence 2.6 4.8 4.1 6.5 7.8 7.7b 12.7
Last month prevalence 1.3 1.0 1.6 4.5 4.1 4.6b 10.9
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Statistically significant changes (p<0.05) between 2010/11 and 2014/15
b Statistically significant differences (p<0.0001) between younger and older groups for 2014/15
The lifetime prevalence of sedatives or tranquillisers for adults aged 15-64 in 2014/15 is 13.1%, 6.1% 
in the last year, and 3.3% used in the last month. There has been no statistically significant change in 
the proportion who ever used in their lifetime (0.8 percentage point decrease since 2010/11), used 
last year (0.4 percentage point decrease since 2010/11) or last month (0.5 percentage point increase).
The prevalence of sedatives or tranquillisers has not changed significantly for males or females since 
2010/11. Prevalence is significantly higher in females than males for lifetime use (15.3% vs. 10.8%), 
last year (7.7% vs. 4.4%) and last month use (4.1% vs. 2.4%).
No significant changes are observed for the prevalence of sedatives or tranquillisers use in younger or 
older adults since 2010/11. For young adults 8.9% reported ever using in their lifetime, 4.1% used in 
the last year and 1.6% in the last month prior to the survey. For older adults 16.3% reported ever using 
in their lifetime, 7.7% used in the last year and 4.6% last month. All prevalence rates are significantly 
higher for older adults than younger adults.
Over 65s report the highest levels of use with 21.4% reporting lifetime use, 12.7% in the last year 
and 10.9% in the last month.
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Table 1.2.1: Anti-Depressants Prevalence Rates (Adults 15-64) by Gender (%)
All adults (15-64) Male (15-64) Female (15-64)
06/07 10/11 14/15 06/07 10/11 14/15 06/07 10/11 14/15
Total Weighted N (valid responses) 4967 5124 5937 2513 2553 2957 2454 2571 2980
Lifetime prevalence (Ever used) 9.3 10.4 11.6 5.9 8.3 8.6 12.6 12.4 14.5*a
Last year prevalence 4.4 4.8 5.9* 3.0 4.0 4.8 5.7 5.6 7.0a
Last month prevalence 3.2 4.1 4.8 2.3 3.2 3.9 4.0 5.0 5.7a
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Statistically significant changes (p<0.05) between 2010/11 and 2014/15
a Statistically significant differences (p<0.01) between males and females were found for 2014/15 data
Table 1.2.2: Anti-Depressants Prevalence Rates (Adults 15+) by Age (%)
Young Adults 15-34 Older Adults 35-64 65+
06/07 10/11 14/15 06/07 10/11 14/15 14/15
Total Weighted N (valid responses) 2315 2253 2592 2652 2872 3345 1039
Lifetime prevalence (Ever used) 7.3 6.8 8.3 11.1 13.2 14.2b 10.5
Last year prevalence 3.4 3.0 4.0 5.3 6.2 7.4b 5.0
Last month prevalence 2.3 2.3 3.0 4.0 5.5 6.2b 4.8
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Statistically significant changes (p<0.05) between 10/11 and 14/15
b statistically significant differences (p<0.0001) between younger and older groups for 2014/15
The lifetime prevalence of anti-depressant use for those aged 15-64 in 2014/15 is 11.6%, last year use 
is 5.9% and 4.8% used last month. There has been a statistically significant change in the proportion of 
adults who used in the last year (1.1 percentage point increase since 2010/11).
Prevalence of use of anti-depressants is significantly higher for females than males, with 7.0% of females 
using in the last year compared to 4.8% of males. Lifetime prevalence has increased significantly for 
females (14.5% up from 12.4% in 2010/11).
No significant changes occurred in prevalence of anti-depressant use in younger or older adults since 
2010/11. For young adults 8.3% report lifetime use, 4% used last year and 3% in the last month. 
For older adults 14.2% reported lifetime use, 7.4% used in the last year and 6.2% used last month. 
All prevalence rates are significantly higher for older adults than for younger adults.
Of those aged over 65, 10.5% report use of anti-depressants in their lifetime, 5% used in the last year 
and 4.8% in the last month.
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Table 1.3.1: Other Opiates Prevalence Rates (Adults 15-64) by Gender (%)
All adults (15-64) Male (15-64) Female (15-64)
02/03 06/07 10/11 14/15 02/03 06/07 10/11 14/15 02/03 06/07 10/11 14/15
Total Weighted N (valid 
responses)
4918 4967 5127 5937 2470 2513 2553 2957 2448 2454 2574 2980
Lifetime prevalence 
(Ever used)
3.0 6.2 38.8 63.8 2.0 4.8 35.2 59.4 3.9 7.6 42.4 68.2a
Last year prevalence 0.5 2.2 27.9 45.8 0.4 1.5 24.0 40.5 0.5 2.8 31.7 51.1a
Last month prevalence 0.2 0.9 14.2 21.0 0.2 0.9 11.1 16.3 0.1 1.0 17.1 25.6a
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
a Statistically significant differences (p<0.0001) between males and females were found for 2014/15 data
Table 1.3.2: Other Opiates Prevalence Rates (Adults 15+) by Age (%)
Young Adults 15-34 Older Adults 35-64 65+
02/03 06/07 10/11 14/15 02/03 06/07 10/11 14/15 14/15
Total Weighted N (valid responses) 2333 2315 2254 2592 2585 2652 2873 3345 1039
Lifetime prevalence (Ever used) 2.9 4.6 37.0 62.6 3.0 7.6 40.2 64.6 49.0
Last year prevalence 0.6 1.7 28.3 48.6 0.4 2.5 27.6 43.6b 29.7
Last month prevalence 0.1 0.8 14.2 22.4 0.2 1.1 14.1 19.9 13.5
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
b statistically significant differences (p<0.01) between younger and older groups for 2014/15
The results for other opiates are not comparable with previous prevalence surveys due to wording and 
show card changes. In 2010/11 the survey specifically asked about substances containing codeine. 
There were further changes to the show card in 2014/15 (see show card 138 in the appendix).
Overall 63.8% report lifetime use of other opiates, 45.8% report use in the last year and 21% in the 
last month.
Over half of females report using other opiates in the last year (51.1%) and over one quarter used in the 
month before the survey (25.6%). Male prevalence rates are significantly lower than females with 40.5% 
reporting use in the last year and 16.3% in the last month.
For young adults 62.6% report lifetime use of other opiates, 48.6% used in the last year and 22.4% in 
the last month. Among older adults 64.6% report lifetime use, 43.6% used in the last year and 19.9% 
in the last month. Young adults report significantly higher rates of last year use than older adults.
Last year prevalence of use of other opiates in those aged over 65 is 29.7%, lower than the young adult 
and older adult groups.
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Age of First Use
Table 2.1.1: Age of First Use of Sedatives or Tranquillisers (Lifetime use, Adults 15-64) by Gender (%)
All adults (15-64) Male (15-64) Female (15-64)
06/07 10/11 14/15 06/07 10/11 14/15 06/07 10/11 14/15
Total Weighted N (valid responses) 524 690 753 201 301 301 323 388 452
Median age 30 30 30 29 28 29 31 30 33
Table 2.1.2: Age of First Use of Sedatives or Tranquillisers (Lifetime use, Adults 15+) by Age (%)
Young Adults (15-34) Older Adults (35-64) 65+
06/07 10/11 14/15 06/07 10/11 14/15 14/15
Total Weighted N (valid responses) 136 224 225 388 466 528 211
Median age 22 22 21 35 37 35 60
Table 2.2.1: Age of First Use of Anti-Depressants (Lifetime use, Adults 15-64) by Gender (%)
All adults (15-64) Male (15-64) Female (15-64)
06/07 10/11 14/15 06/07 10/11 14/15 06/07 10/11 14/15
Total Weighted N (valid responses) 455 530 676 149 211 249 306 319 427
Median age 32 30 30 34 34 32 30 30 30
Table 2.2.2: Age of First Use of Anti-Depressants (Lifetime use, Adults 15+) by Age (%)
Young Adults (15-34) Older Adults (35-64) 65+
06/07 10/11 14/15 06/07 10/11 14/15 14/15
Total Weighted N (valid responses) 164 152 210 290 378 465 104
Median age 21 21 22 35 35 35 55
Table 2.3: Age of First Use of Other Opiates (Lifetime use, Adults 15+) by Gender and Age (%)
All 
adults 
(15-64)
Male 
(15-64)
Female 
(15-64)
Young 
Adults 
(15-34)
Older 
Adults 
(35-64)
65+
Total Weighted N (valid responses) 3420 1573 1883 1462 1958 425
Median age 18 18 17 15 20 41
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Age of first use (lifetime use):
The median age for first use of sedatives or tranquillisers by adults aged 15-64 (Tables 2.1.1 & 2.1.2) is 
30 years, for males is 29 and 33 years for females. Age of first use for young adults is 21, compared to 
35 in older adults and 60 in those aged over 65. The median age went up by one year for males since 
the 2010/11 survey and three years for females.
The median age for first use of anti-depressants by adults aged 15-64 (Tables 2.2.1 & 2.2.2) is 30 
years. Median age at first use is higher in males than females (32 vs. 30) and higher in older adults than 
younger adults (35 vs. 22). The median age at first use for those aged over 65 is 55 years. No change 
occurred overall, for females or for older adults since the 2010/11 survey. The median age dropped two 
years for males since 2010/11 and increased by one year for young adults.
The median age of first use of other opiates by adults aged 15-64 (Table 2.3) is 18. The median age of 
first use is 18 for males and 17 for females. For younger adults the median age at first use is 15, for older 
adults is age 20, and for those 65 or over the median age is 41.
Table 3.1.1: Frequency of Use of Sedatives or Tranquillisers per Month (People who used in the last 
month, Adults 15-64) by Gender (%)
All adults (15-64) Male (15-64) Female (15-64)
06/07 10/11 14/15 06/07 10/11 14/15 06/07 10/11 14/15
Total Weighted N (valid responses) 147 142 193 60 58 70 87 85 123
20 days or more 57.1 53.3 58.9 53.3 52.8 68.3 59.8 53.6 53.6
10–19 days 6.2 7.2 9.5 5.0 7.9 10.2 6.9 6.7 9.1
4–9 days 17.0 17.7 11.9 16.7 18.1 6.2 17.2 17.4 15.2
1–3 days 19.7 21.9 19.6 25.0 21.3 15.2 16.1 22.3 22.1
Table 3.1.2: Frequency of Use of Sedatives or Tranquillisers per Month (People who used in the last 
month, Adults 15+) by Age (%)
Young Adults (15-34) Older Adults (35-64) 65+
06/07 10/11 14/15 06/07 10/11 14/15 14/15
Total Weighted N (valid responses) 29 24 40 118 119 153 113
20 days or more 41.4 22.7 39.3 61.0 59.3 64.1 73.5
10–19 days 3.4 14.1 20.2 6.8 5.8 6.7 8.0
4–9 days 17.2 29.6 16.4 16.9 15.3 10.8 6.3
1–3 days 37.9 33.7 24.1 15.3 19.6 18.4 12.2
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
2 The number of people who used sedatives or tranquillisers in the last month in the 2010/11 and 2014/15 surveys is unlikely 
to be sufficient to detect differences where they occur in the population as statistically significant.
Tables 3.1.1 and 3.1.2 show the frequency of use in the month prior to the survey for people who used 
sedatives or tranquillisers in the last month. Overall, 58.9% report using for 20 days or more in the last 
month, and 9.5% report using for 10-19 days. For males 68.3% used sedatives or tranquillisers on 20 or 
more days in the previous month, while 53.6% of females used at the same frequency. Using sedatives 
or tranquillisers for 20 days or more is more common in older adults (64.1%) than younger adults 
(39.3%), and highest in those aged over 65 (73.5%).
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Table 3.2.1: Frequency of Use of Anti-Depressants per Month (People who used in the last month, 
Adults 15-64) by Gender (%)
All adults (15-64) Male (15-64) Female (15-64)
06/07 10/11 14/15 06/07 10/11 14/15 06/07 10/11 14/15
Total Weighted N (valid responses) 152 209 256 56 80 103 94 129 171
20 days or more 91.1 92.4 92.7 87.5 89.5 93.6 94.7 94.3 92.0
10–19 days 4.9 3.0 2.1 7.1 3.8 1.2 3.2 2.5 2.7
4–9 days 1.8 3.3 3.0 1.8 3.5 1.1 1.1 3.2 4.3
1–3 days 2.2 1.2 2.2 3.6 3.1 4.1 1.1 0.0 1.0
Table 3.2.2: Frequency of Use of Anti-Depressants per Month (People who used in the last month, 
Adults 15+) by Age (%)
Young Adults (15-34) Older Adults (35-64) 65+
06/07 10/11 14/15 06/07 10/11 14/15 14/15
Total Weighted N (valid responses) 51 51 77 101 158 206 50
20 days or more 92.2 92.3 90.2 90.1 92.5 93.6 91.2
10–19 days 5.9 0.0 2.6 5.0 4.0 1.9 4.1
4–9 days 2.0 7.7 4.6 2.0 1.9 2.5 3.9
1–3 days 0.0 0.0 2.6 3.0 1.6 2.1 0.8
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
2 The number of people who used sedatives or tranquillisers in the last month in the 2010/11 and 2014/15 surveys is unlikely to be 
sufficient to detect differences where they occur in the population as statistically significant.
Tables 3.2.1 and 3.2.2 show the frequency of use in the month prior to the survey for people who used 
anti-depressants in the last month. Overall, 92.7% of adults report using for 20 days or more in the last 
month. For males 93.6% used anti-depressants on 20 or more days in the previous month, while 92% 
of females used at the same frequency. The proportion of young adults who used on 20 days or more 
in the last month is 90.2%, while 93.6% of older adults and 91.2% of those aged over 65 used at the 
same frequency.
Table 3.3: Frequency of Use of Other Opiates per Month (People who used in the last month) 
by Gender and Age (%)
All 
adults 
(15-64)
Male 
(15-64)
Female 
(15-64)
Young 
Adults 
(15-34)
Older 
Adults 
(35-64)
65+
Total Weighted N (valid responses) 1238 476 762 575 663 137
20 days or more 6.2 5.9 6.4 2.9 9.1 28.5
10–19 days 8.1 7.8 8.3 8.3 7.9 11.8
4–9 days 26.9 28.9 25.6 27.6 26.2 24.9
1–3 days 58.8 57.5 59.7 61.2 56.8 34.7
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 3.4 shows the frequency of use in the month prior to the survey for people who used other opiates 
in the last month. The majority (58.8%) of those in this group aged 15-64 report using other opiates 
for 1-3 days in the month prior to the survey. For males 57.5% used other opiates for 1-3 days in the 
previous month, while 59.7% of females used at the same frequency. Using other opiates for 20 days or 
more is more common in older adults (9.1%) than younger adults (2.9%). Use of other opiates for 20 
days or more is highest for those aged 65 or over (28.5%).
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Method by which prescription drugs are taken
Table 4.1: Method of taking Sedatives or Tranquillisers (People who used in the last month) (%)
All 
Adults 
(15+)
Male 
(15+)
Female 
(15+)
Young 
Adults 
(15-34)
Older 
Adults 
(35-64)
65+
Total Weighted N (valid responses) 309 104 205 40 153 113
Oral (Tablets or Syrup) 99.3 99.4 99.3 100 98.9 99.6
Injection with a needle 0.3 0.0 0.5 0.0 0.7 0.0
Other 0.3 0.6 0.2 0.0 0.4 0.4
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
People who used sedatives or tranquillisers in the last month were asked about the most common 
method used to take sedatives or tranquillisers. The majority report taking sedatives or tranquillisers orally 
(Tablets or Syrup) (99.3%), while 0.3% said they inject and 0.3% indicated they use another method.
Table 4.2: Method of taking Anti-Depressants (People who used in the last month) (%)
All 
Adults 
(15+)
Male 
(15+)
Female 
(15+)
Young 
Adults 
(15-34)
Older 
Adults 
(35-64)
65+
Total Weighted N (valid responses) 335 125 210 79 206 50
Oral (tablets or Syrup 99.7 100 99.5 100 99.5 100.0
Injection with a needle 0.3 0.0 0.5 0.0 0.5 0.0
Other 0.0 0.0 0.0 0.0 0.0 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
People who used anti-depressants in the last month were asked about the most common method used 
to take anti-depressants. The majority report taking anti-depressants orally (Syrup or tablet) (99.7%), 
while 0.3% said they inject.
How prescription drugs were obtained on last occasion used
Table 5.1: How Sedatives or Tranquillisers were Obtained on Last Occasion Used (People who used 
in the last year) (%)
All 
Adults 
(15+)
Male 
(15+)
Female 
(15+)
Young 
Adults 
(15-34)
Older 
Adults 
(35-64)
65+
309 104 205 40 153 113
I got them on a prescription 94.6 93.6 95.1 89.9 92.7 98.6
I got them from someone I know 3.1 6.4 1.4 10.1 3.6 0.0
I bought them without a prescription in a chemist 2.0 0.0 3.1 0.0 3.1 1.4
I bought them over the internet 0.0 0.0 0.0 0.0 0.0 0.0
Other 0.3 0.0 0.4 0.0 0.6 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
People who used sedatives or tranquillisers in the last year were asked how they got their sedatives 
or tranquillisers the last time they used. The majority report getting sedatives or tranquillisers on a 
prescription (94.6%), followed by getting them from someone they know (3.1%), bought without a 
prescription in a chemist (2.0%), and 0.3% state they obtained them in other ways. Males are more 
likely to report getting sedatives or tranquillisers from someone they know (6.4% of males vs. 1.4% of 
females), and young adults are more likely than older adults to report the same (10.1% of young adults 
vs. 3.6% of older adults report getting sedatives or tranquillisers from someone they know).
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Table 5.2: How Anti-Depressants were Obtained on Last Occasion Used (People who used in the 
last year) (%)
All 
Adults 
(15+)
Male 
(15+)
Female 
(15+)
Young 
Adults 
(15-34)
Older 
Adults 
(35-64)
65+
335 125 210 79 206 50
I got them on a prescription 98.5 100 97.5 97.6 98.4 100
I got them from someone I know 1.0 0.0 1.5 2.4 0.6 0.0
I bought them without a prescription in a chemist 0.2 0.0 0.4 0.0 0.4 0.0
I bought them over the internet 0.4 0.0 0.6 0.0 0.6 0.0
Other 0.0 0.0 0.0 0.0 0.0 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses0
People who used anti-depressants in the last year were asked how they got their anti-depressants the 
last time they used. The majority report getting anti-depressants on a prescription (98.5%), followed 
by getting them from someone they know (1%), buying them on the internet (0.4%), and without a 
prescription in a chemist (0.2%).
Table 5.3: How Other Opiates were Obtained on Last Occasion Used (People who used in the last year) 
(%)
All 
Adults 
(15+)
Male 
(15+)
Female 
(15+)
Young 
Adults 
(15-34)
Older 
Adults 
(35-64)
65+
1388 533 856 579 665 140
I got them on a prescription 30.0 29.8 30.0 21.8 30.9 59.3
I got them from someone I know 3.1 3.2 3.1 4.8 2.0 2.0
I bought them without a prescription in a chemist 64.4 65.2 63.9 70.4 64.8 37.6
I bought them over the internet 0.0 0.0 0.0 0.0 0.0 0.0
Other 2.5 1.8 2.9 3.0 2.3 1.1
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
People who used other opiates in the last year were asked how they got other opiates the last time they 
used. The majority report getting other opiates without a prescription in a chemist (64.4%), followed 
by getting them on a prescription (30%), getting them from someone they know (3.1%) and other 
unspecified sources (2.5%). Males and females had broadly similar results. Those aged over 65 were 
most likely to report getting other opiates on prescription (59.3% vs. 30.9% of older adults, and 21.8% 
of young adults).
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Prescription Drug Prevalence by Socio-economic Group 
(SOC2000 Classification)
Table 6.1: Sedative or Tranquilliser Prevalence by Socio-Economic Group (SOC2000 Classification) (%)
Lifetime* Last year* Last 
month*
A: Professional, senior management, top civil servants (n=192) 13.8 5.5 1.6
B: Middle management, senior civil servants, managers and owners of own 
business (n=1046)
15.6 7.0 3.6
C1: Junior management and owners of small business (n=1913) 14.0 6.4 3.4
C2: Skilled manual workers and manual workers responsible for other 
workers (n=1304)
11.2 5.3 2.9
D: Semi-Skilled and unskilled manual workers, trainees and apprentices 
(n=925)
9.5 5.2 3.4
E: All those dependent on the state long term (n=1266) 21.8 12.3 9.4
F1: Farmer 50+ acres (n=254) 9.3 5.0 3.1
F2: Farmer <50 acres (n=104) 11.4 4.8 4.8
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Analysis of sedative or tranquilliser prevalence by socio-economic group status shows that lifetime 
(21.8%), last year (12.3%) and last month rates (9.4%) are highest in Group E (All those dependent 
on the state long term). Lifetime prevalence is lowest for Group F1 (farmers with more than 50 acres) 
(9.3%), and last year prevalence is lowest for Group F2 (farmers with less than 50 acres) (4.8%). Last 
month prevalence (1.6%) is lowest for Group A (professionals, senior management & top civil servants). 
Group differences are statistically significant for lifetime, last year and last month prevalence.
Table 6.2: Anti-Depressants Prevalence by Socio-Economic Group (SOC2000 Classification) (%)
Lifetime* Last year* Last 
month*
A: Professional, senior management, top civil servants (n=192) 7.5 2.9 2.9
B: Middle management, senior civil servants, managers and owners of own 
business (n=1046)
8.3 4.7 3.6
C1: Junior management and owners of small business (n=1913) 10.9 4.4 3.8
C2: Skilled manual workers and manual workers responsible for other 
workers (n=1304)
10.3 5.5 4.3
D: Semi-Skilled and unskilled manual workers, trainees and apprentices 
(n=925)
9.2 5.0 4.1
E: All those dependent on the state long term (n=1266) 19.4 10.4 9.0
F1: Farmer 50+ acres (n=254) 7.4 3.7 2.0
F2: Farmer <50 acres (n=104) 7.0 5.0 5.0
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Analysis of anti-depressant prevalence by socio-economic group status shows that lifetime (19.4%), last 
year (10.4%) and last month rates (9%) are highest in Group E (All those dependent on the state long 
term). Lifetime prevalence rates are lowest for Group F2 (farmers with less than 50 acres) (7%). Use 
of anti-depressants in the last year is highest for Group A (professional, senior management & top civil 
servants) (2.9%) and last month rates are lowest for Group F1 (farmers with more than 50 acres) (2%). 
Group differences are statistically significant for lifetime, last year and last month prevalence.
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Table 6.3: Other Opiates Prevalence by Socio-Economic Group (SOC2000 Classification) (%)
Lifetime* Last year* Last 
month*
A: Professional, senior management, top civil servants (n=192) 63.5 37.4 22.4
B: Middle management, senior civil servants, managers and owners of own business 
(n=1046)
71.3 53.0 22.4
C1: Junior management and owners of small business (n=1913) 64.7 46.5 21.9
C2: Skilled manual workers and manual workers responsible for other workers 
(n=1304)
60.2 41.6 18.1
D: Semi-Skilled and unskilled manual workers, trainees and apprentices (n=925) 55.3 38.1 16.6
E: All those dependent on the state long term (n=1266) 56.0 38.6 20.4
F1: Farmer 50+ acres (n=254) 55.2 39.9 15.1
F2: Farmer <50 acres (n=104) 54.1 36.2 8.7
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Due to weighting, categories do not always sum to weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Those in Group B (Middle management, senior civil servants, managers and owners of own business) 
are most likely to ever take other opiates in their lifetime (71.3%), and are also most likely to report last 
year use (53%). Group B and Group A (professional, senior management & top civil servants) report the 
highest rate of other opiate use in the last month (both 22.4%). Lifetime (54.1%), last year (36.2%) and 
last month (8.7%) rates are lowest for group F2 (farmers with less than 50 acres). Group differences are 
statistically significant for lifetime, last year and last month prevalence.
Work Status
Table 7.1: Sedatives or Tranquilliser Prevalence by Work Status (%)
Lifetime* Last year* Last month*
At work (n=3600) 11.5 4.7 2.0
Unemployed (n=646) 17.3 8.4 5.0
Student (n=802) 4.8 2.0 0.6
Engage in home duties (n=852) 18.1 10.4 7.3
Retired (n=853) 21.3 11.9 10.4
Other (n=251) 41.8 27.0 19.9
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Lifetime (41.8%), last year (27%) and last month (19.9%) prevalence rates for sedative or 
tranquilliser use are highest among those classified as being in the ‘other’ group. Those who are 
retired report the next highest rate of use of sedatives or tranquillisers for lifetime (21.3%), last year 
(11.9%) and last month (10.4%). Prevalence rates are lowest amongst students. Group differences 
are statistically significant for all prevalence measures.
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Table 7.2: Anti-Depressants Prevalence by Work Status (%)
Lifetime* Last year* Last month*
At work (n=3600) 9.0 3.9 3.1
Unemployed (n=646) 17.2 9.6 7.7
Student (n=802) 5.1 2.9 1.9
Engage in home duties (n=852) 17.6 8.7 7.7
Retired (n=853) 10.1 5.1 4.5
Other (n=251) 35.2 23.8 20.8
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Prevalence rates of anti-depressant use are highest among those classified as being in the ‘other’ group. 
The next highest rates of anti-depressant use are seen in those who are engaged in home duties and 
the unemployed with 7.7% of both groups reporting last month use of anti-depressants. Lifetime (5.1%), 
last year (2.9%), and last month prevalence (1.9%) are lowest amongst students. Group differences are 
statistically significant for all three prevalence measures.
Table 7.3: Other Opiates Prevalence by Work Status (%)
Lifetime* Last year* Last month
At work (n=3600) 64.9 46.2 19.9
Unemployed (n=646) 59.3 40.4 18.8
Student (n=802) 60.9 48.6 23.3
Engage in home duties (n=852) 59.9 43.1 21.3
Retired (n=853) 51.6 29.2 13.3
Other (n=251) 59.9 43.2 28.9
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Lifetime (64.9%) prevalence rate of other opiates is highest for those at work, last year prevalence (48.6%) 
is highest for students, and last month prevalence (28.9%) is highest among those classified as being 
in the ‘other’ group. Lifetime (51.6%), last year (29.2%) and last month (13.3%) prevalence rates are 
lowest for those who are retired. Group differences are significant for lifetime use and use in the last year.
Housing tenure
Table 8.1: Sedative or Tranquilliser Prevalence by Housing Tenure (%)
Lifetime* Last year* Last month*
Owned in part or full (n=4357) 15.1 7.7 5.2
Rented from private landlord (n=1221) 14.0 5.6 2.5
Rented from LA/HA (n=479) 20.4 12.2 8.6
Other (n=65) 21.5 10.5 6.4
Live with parents/other family (n=883) 7.0 3.0 1.0
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
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Table 8.1 presents sedative or tranquilliser prevalence rates according to type of housing tenure. Lifetime 
rates for sedative or tranquilliser prevalence are highest in the group classified as ‘others’ (21.5%). Last 
year (12.2%) and last month (8.6%) prevalence are highest for those renting from Local Authority/
Housing Authority. Lifetime (7%), last year (3%), and last month (1%) prevalence rates are lowest 
for those who live with parents/other family. Group differences are statistically significant for all three 
prevalence measures.
Table 8.2: Anti-Depressant Prevalence by Housing Tenure (%)
Lifetime* Last year* Last month*
Owned in part or full (n=4357) 10.8 5.4 4.7
Rented from private landlord (n=1221) 12.5 5.9 4.6
Rented from LA/HA (n=479) 24.5 12.9 9.9
Other (n=65) 14.2 7.9 6.0
Live with parents/other family (n=883) 5.7 3.4 2.5
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 8.2 presents anti-depressant prevalence rates according to type of housing tenure. Lifetime use 
of anti-depressants (24.5%), last year use (12.9%) and last month use (9.9%) are highest for those 
renting from Local Authority/Housing Authority. Lifetime (5.7%), last year (3.4%), and last month (2.5%) 
prevalence rates are lowest for those who live with parents/other family. Group differences are statistically 
significant for all three prevalence measures.
Table 8.4: Other Opiates Prevalence by Housing Tenure (%)
Lifetime* Last year* Last month
Owned in part or full (n=4357) 63.2 43.1 20.0
Rented from private landlord (n=1221) 55.0 39.0 18.8
Rented from LA/HA (n=479) 58.9 40.3 18.0
Other (n=65) 62.5 41.9 13.7
Live with parents/other family (n=883) 63.7 52.4 22.1
* Wald-F statistical significance test (p <0.01) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 8.4 presents other opiate prevalence rates according to type of housing tenure. Lifetime (63.7%), 
last year (52.4%) and last month (22.1%) prevalence rates for other opiate prevalence are highest 
for those living with parents/other family. Lifetime (55%), and last year (39%) prevalence rates are 
lowest for those renting from a private landlord. Last month (13.7%) prevalence is lowest among those 
classified in the ‘other’ category. Group differences are statistically significant for lifetime and last year 
prevalence measures.
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Age Ceased Education
Table 9.1: Sedative or Tranquilliser Prevalence by Age Education Ceased (%)
Lifetime* Last year* Last month*
15 years and under (n=755) 20.0 11.7 9.5
16-19 years (n=2361) 15.3 7.7 5.0
20 years and over (n=2482) 14.3 6.6 3.8
* Wald-F statistical significance test (p <0.01) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 9.1 describes sedative or tranquilliser prevalence by the age that formal education was ceased. 
Lifetime (20%), last year (11.7%) and last month (9.5%) sedative or tranquilliser prevalence is highest 
among those who ceased education at 15 years and under. Lifetime (14.3%), last year (6.6%) and last 
month (3.8%) rates were lowest for those whose education ceased aged 20 or older. Group differences 
in all three prevalence rates are statistically significant.
Table 9.2: Anti-Depressant Prevalence by Age Education Ceased (%)
Lifetime Last year* Last month*
15 years and under (n=755) 13.2 8.2 7.4
16-19 years (n=2361) 13.0 7.0 6.0
20 years and over (n=2482) 10.7 4.6 3.7
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 9.2 describes anti-depressant prevalence by the age that formal education was ceased. Lifetime 
(13.2%), last year (8.2%) and last month (7.4%) anti-depressant prevalence is highest among those 
who ceased education at 15 years and under. Lifetime (10.7%), last year (4.6%) and last month (3.7%) 
rates were lowest for those whose education ceased aged 20 or older. Group differences in prevalence 
rates are statistically significant for last year and last month prevalence.
Table 9.3: Other Opiates Prevalence by Age Education Ceased (%)
Lifetime* Last year* Last month
15 years and under (n=755) 50.9 31.7 17.5
16-19 years (n=2361) 61.2 41.0 19.0
20 years and over (n=2482) 65.3 46.7 20.3
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 9.3 describes other opiates prevalence by the age that formal education was ceased. Lifetime 
(65.3%), last year (46.7%) and last month (20.3%) other opiates prevalence rates are highest among 
those who ceased education at 20 years and over. Lifetime (50.9%), last year (31.7%) and last month 
(17.5%) rates are lowest for those whose education ceased aged 15 or under. Group differences in 
prevalence rates are statistically significant for lifetime and last year prevalence.
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Highest Education Level Attained
Table 10.1: Sedative or Tranquilliser Prevalence by Highest Education Level Attained (%)
Lifetime* Last year* Last month*
No formal education/primary (n=504) 20.3 12.7 10.5
Lower secondary (n=1376) 14.8 7.5 5.2
Upper Secondary (n=2012) 11.8 6.0 3.5
Third level (n=3088) 14.8 6.7 3.6
* Wald-F statistical significance test (p <0.01) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 10.1 presents sedative or tranquilliser prevalence rates according to the highest level of qualification 
attained by respondents. Lifetime (20.3%), last year (12.7%) and last month (10.5%) rates are highest 
for those with no formal education/primary education. Lifetime (11.8%), last year (6%) and last month 
(3.5%) prevalence rates are lowest for those whose highest level of education is upper secondary. 
Group differences in all three prevalence rates are statistically significant.
Table 10.2: Anti-Depressant Prevalence by Highest Education Level Attained (%)
Lifetime Last year Last month
No formal education/primary (n=504) 12.6 6.8 6.1
Lower secondary (n=1376) 12.3 6.8 5.4
Upper Secondary (n=2012) 10.4 5.3 4.7
Third level (n=3088) 11.6 5.5 4.4
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 10.2 presents anti-depressant prevalence rates according to the highest level of education attained 
by respondents. Lifetime (12.6%) and last month (6.1%) rates are highest for those with no formal 
education/primary education. Last year rate are highest for those who have lower secondary education 
only, and those with no formal education/primary education (both 6.8%). Lifetime (10.4%), and last 
year (5.3%) prevalence rates are lowest for those whose highest level of education is upper secondary. 
Lowest last month (4.4%) prevalence rates are seen in those with third level education.
Table 10.3: Other Opiates Prevalence by Highest Education Level Attained (%)
Lifetime* Last year* Last month*
No formal education/primary (n=504) 43.7 25.7 13.3
Lower secondary (n=1376) 59.4 41.5 20.3
Upper Secondary (n=2012) 59.7 41.9 19.3
Third level (n=3088) 66.7 48.2 21.2
* Wald-F statistical significance test (p <0.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 10.3 presents other opiate prevalence rates according to the highest level of education attained 
by respondents. Lifetime (66.7%), last year (48.2%) and last month (21.2%) rates are highest for 
those whose highest level of education is third level. Lifetime (43.7%), last year (25.7%) and last 
month (13.3%) prevalence rates are lowest for those who have no formal education/primary education. 
Group differences in all three prevalence rates are statistically significant.
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Marital Status
Table 11.1: Sedative or Tranquilliser Prevalence by Marital Status (%)
Lifetime* Last year* Last month*
Single/never married (n=2231) 10.2 4.9 2.6
married (n=3531) 14.2 6.7 4.1
Cohabiting (n=610) 16.2 7.3 3.4
Separated (n=187) 22.8 12.9 8.9
Divorced (n=115) 39.0 19.8 12.6
Widowed (n=315) 27.3 18.2 15.9
* Wald-F statistical significance test (p<0.0001) for a test of equality among groups.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 11.1 shows results for sedative or tranquilliser prevalence according to respondents’ marital status. 
Lifetime usage rates are highest among those classified as divorced (39%), followed by those who are 
widowed (27.3%). Last year rates were also highest for these groups (19.8% and 18.2% respectively) 
and last month rates were highest among those widowed and divorced (15.9% and 12.5% respectively). 
For all three prevalence measures, group differences are statistically significant.
Table 11.2: Anti-Depressant Prevalence by Marital Status (%)
Lifetime* Last year* Last month*
Single/never married (n=2231) 9.1 5.1 4.1
married (n=3531) 10.9 5.7 4.8
Cohabiting (n=610) 13.3 4.3 3.1
Separated (n=187) 32.0 16.0 13.9
Divorced (n=115) 26.0 9.3 7.6
Widowed (n=315) 12.7 6.3 6.0
* Wald-F statistical significance test (p<0.001) for a test of equality among groups.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 11.2 shows results for anti-depressant prevalence according to respondents’ marital status. Lifetime 
prevalence rates are highest among those who are separated (32%), followed by those classified as 
divorced (26%). Last year rates were highest for these groups (16% and 9.3% respectively) as were 
last month rates (13.9% and 7.6% respectively). For all three prevalence measures, group differences 
are statistically significant.
Table 11.3: Other Opiate Prevalence by Marital Status (%)
Lifetime* Last year* Last month
Single/never married (n=2231) 61.4 47.6 20.7
married (n=3531) 62.0 41.6 19.4
Cohabiting (n=610) 64.1 44.6 20.5
Separated (n=187) 66.5 46.2 23.3
Divorced (n=115) 64.2 42.2 22.6
Widowed (n=315) 49.7 31.1 15.9
* Wald-F statistical significance test (p<0.0001) for a test of equality among groups.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Table 11.3 shows results for other opiate prevalence according to respondents’ marital status. Lifetime 
(66.5%) and last month (23.3%) rates are highest among those classified as separated. Last year 
prevalence rates are highest for those who are single/never married (47.6%). Lifetime (49.7%), last 
year (31.1%) and last month (15.9%) prevalence rates are lowest for those classified as widowed. 
For lifetime and last year prevalence measures, group differences are statistically significant.
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Appendix: Showcard presented to respondents as part of the 
2014/15 survey
Showcard 138
Codeine Opiates (excluding heroin & methadone)
Df 118 30 Tablets Temgesic ®
Feminax Tablets Kapake ®
Kapake Morphine
Migraleve Opium
Nurofen Plus DF118 ® (DF’s)
Panadeine Tablets Diffs
Paracodin Dikes
Paramol Peach
Solpadeine Fentanyl (Durogesic ® & Sublimaze ® & Actiq ®)
Solpadol Oxycodone (Oxycontin ® & Oxynorm ®)
Syndol MST ® (MST’s)
Tylex Buprenorphine (Subutex ®)
Uniflu Plus with Vitamin C Diconal ®
Veganin Plus Pethidine
Tramadol Napps
Showcard 16
Sedatives Benzos
Sleeping pills Roches
Rohypnol ® Librium ®
Roofies Valium ®, (Diazepam) D5/D10
Row rows Normison ®, (Duck eggs), Temazepam
Dalmane ®, Flurazepam Ativan ®
Mogadon ®, (Moggies), Nitrazepam Halcion ®, Triazolam
Phenobarbitone Xanax ®
Tranquillisers Stilnoct ®, Zolpidem
Tranks Zimovane ®, Zopiclone
Downers
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